SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 24, 2025-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today

Company is awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health and certified as a Great Place to Work ® Recognition underscores commitment to mission-driven culture and exceptional support for employee mental health SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul.

Accomplished biopharma executive brings nearly 30 years of experience in business development, enterprise strategy, and global partnerships to her role Ms. Cote to help drive the strategic positioning of Vistagen’s clinical-stage pipeline, which includes five novel intranasal pherine candidates

Topline results of PALISADE-3 Phase 3 Trial of fasedienol for acute treatment of social anxiety disorder expected in the fourth quarter of this year PALISADE-4 Phase 3 Trial topline results expected in the first half of 2026 Company showcases promising clinical-stage pipeline of five novel

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 12, 2025-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today

Company’s PALISADE-4 Phase 3 trial now expected to read out in the first half of 2026 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 2, 2025-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 28, 2025-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced

Posters Highlight New Insights into Social Anxiety Disorder and the Novel Mechanism of Action of Itruvone to Treat Major Depressive Disorder SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 23, 2025-- Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with

New Data Build on Recent Epidemiology Findings Presented by the Company at the 2024 Neuroscience Education Institute Congress The Need for Improved Diagnosis and Treatment Options Underscored by Data Presented in Posters SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr.

Posters Highlight New Insights into Social Anxiety Disorder SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 19, 2025-- Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of